Literature DB >> 16425369

Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.

Terence C W Poon1, Clarissa H S Chiu, Paul B S Lai, Tony S K Mok, Benny Zee, Anthony T C Chan, Joseph J Y Sung, Philip J Johnson.   

Abstract

AIM: To investigate the correlation between tissue ST6Gal I and serum msAFP in HCC patients, and to investigate their prognostic significance.
METHODS: Preoperative sera, paired tumorous and non-tumorous tissues were collected from 19 consecutive patients who had undergone surgical resection of HCC. ST6Gal I activities in the tissues were measured by an in vitro microsomal enzyme activity assay. The percentages of tumor-specific msAFP in the sera were also estimated by an isoelectric focusing-immunoblotting assay.
RESULTS: The tumor ST6Gal I activity was negatively correlated with serum msAFP percentage (r = -0.53, P = 0.019). Both decreased tumor ST6Gal I activity and increased serum msAFP percentage were associated with poor tumor cell differentiation. Univariate analyses showed that both decreased tumor ST6Gal I activity (P = 0.028), increased serum msAFP percentage (P = 0.034) and poor tumor cell differentiation (P = 0.031) were associated with shorter overall survival. Multivariate analysis using the Cox regression model showed that the preoperative serum msAFP percentage (P = 0.022) and tumor cell differentiation status (P = 0.048) were independent prognostic indicators for patient overall survival.
CONCLUSION: Our results indicate that the presence of msAFP in blood circulation is associated with a decreased activity of ST6Gal I activity in HCC. Both tissue ST6Gal I and serum msAFP are potential prognostic markers for patients with operable HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425369      PMCID: PMC4355769          DOI: 10.3748/wjg.v11.i42.6701

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells.

Authors:  N Le Marer; V Laudet; E C Svensson; H Cazlaris; B Van Hille; C Lagrou; D Stehelin; J Montreuil; A Verbert; P Delannoy
Journal:  Glycobiology       Date:  1992-02       Impact factor: 4.313

2.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.

Authors:  J C Sheu; J L Sung; D S Chen; P M Yang; M Y Lai; C S Lee; H C Hsu; C N Chuang; P C Yang; T H Wang
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

3.  Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo.

Authors:  H Yamamoto; A Oviedo; C Sweeley; T Saito; J R Moskal
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Enhanced CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity of human colon cancer xenografts in athymic nude mice and of xenograft-derived cell lines.

Authors:  F Dall'Olio; N Malagolini; F Serafini-Cessi
Journal:  Int J Cancer       Date:  1992-01-21       Impact factor: 7.396

5.  Regulated expression of alpha 2,6-sialyltransferase by the liver-enriched transcription factors HNF-1, DBP, and LAP.

Authors:  E C Svensson; P B Conley; J C Paulson
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

6.  Alpha-fetoprotein concentrations measured by radioimmunoassay in diagnosing and excluding hepatocellular carcinoma.

Authors:  P J Johnson; B Portmann; R Williams
Journal:  Br Med J       Date:  1978-09-02

7.  Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein.

Authors:  Terence C W Poon; Tony S K Mok; Anthony T C Chan; Charles M L Chan; Veronica Leong; Steven H T Tsui; Thomas W T Leung; Herman T M Wong; Stephen K W Ho; Philip J Johnson
Journal:  Clin Chem       Date:  2002-07       Impact factor: 8.327

8.  Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer.

Authors:  M A Recchi; M Hebbar; L Hornez; A Harduin-Lepers; J P Peyrat; P Delannoy
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

9.  Structures of disease-specific serum alpha-fetoprotein isoforms.

Authors:  P J Johnson; T C Poon; N M Hjelm; C S Ho; C Blake; S K Ho
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour.

Authors:  P J Johnson; T C Poon; N M Hjelm; C S Ho; S K Ho; C Welby; D Stevenson; T Patel; R Parekh; R R Townsend
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  9 in total

1.  Platelets support extracellular sialylation by supplying the sugar donor substrate.

Authors:  Melissa M Lee; Mehrab Nasirikenari; Charles T Manhardt; David J Ashline; Andrew J Hanneman; Vernon N Reinhold; Joseph T Y Lau
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

2.  Expression patterns of α2,3-sialyltransferase I and α2,6-sialyltransferase I in human cutaneous epithelial lesions.

Authors:  S A Ferreira; J L A Vasconcelos; R C W C Silva; C L B Cavalcanti; C L Bezerra; M J B M Rêgo; E I C Beltrão
Journal:  Eur J Histochem       Date:  2013-02-14       Impact factor: 3.188

3.  Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin β1 and migration in colon cancer cells.

Authors:  Minyoung Lee; Jung-Jin Park; Young-Gyu Ko; Yun-Sil Lee
Journal:  Radiat Oncol       Date:  2012-03-27       Impact factor: 3.481

4.  ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.

Authors:  Daniel R Christie; Faheem M Shaikh; John A Lucas; John A Lucas; Susan L Bellis
Journal:  J Ovarian Res       Date:  2008-10-01       Impact factor: 4.234

5.  α2,6-Sialylation mediates hepatocellular carcinoma growth in vitro and in vivo by targeting the Wnt/β-catenin pathway.

Authors:  Y Zhao; A Wei; H Zhang; X Chen; L Wang; H Zhang; X Yu; Q Yuan; J Zhang; S Wang
Journal:  Oncogenesis       Date:  2017-05-29       Impact factor: 7.485

6.  B cells suppress medullary granulopoiesis by an extracellular glycosylation-dependent mechanism.

Authors:  Eric E Irons; Melissa M Lee-Sundlov; Yuqi Zhu; Sriram Neelamegham; Karin M Hoffmeister; Joseph Ty Lau
Journal:  Elife       Date:  2019-08-13       Impact factor: 8.140

7.  Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma.

Authors:  Ruijia Liu; Xu Cao; Yijun Liang; Xiaobin Li; Qian Jin; Ying Li; Hongbo Du; Xiaobin Zao; Yong'an Ye
Journal:  J Inflamm Res       Date:  2022-10-10

8.  Overexpression of ST3Gal-I promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma.

Authors:  Han Wu; Xue-Liang Shi; Hai-Jian Zhang; Qing-Jie Song; Xiao-Bing Yang; Wei-Dong Hu; Guang-Lin Mei; Xi Chen; Qin-Sheng Mao; Zhong Chen
Journal:  Onco Targets Ther       Date:  2016-04-18       Impact factor: 4.147

Review 9.  Advances in MALDI mass spectrometry in clinical diagnostic applications.

Authors:  Eddy W Y Ng; Melody Y M Wong; Terence C W Poon
Journal:  Top Curr Chem       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.